Genentech Plans $750 Million Device Manufacturing Facility in Oregon

Genentech, a member of the Roche Group, plans to invest approximately $750 million to build a new device fill-finish manufacturing facility at its campus in Hillsboro, Oregon.

The new facility will add end-to-end manufacturing capabilities for drug delivery devices and expand production capacity for Roche and Genentech’s future medicines. Commercial operations are expected to begin in 2031.

The investment is expected to create around 250 high-paying manufacturing jobs in Oregon. The construction phase is also expected to create approximately 200 jobs as the new facility is developed.

The Hillsboro site will manufacture advanced drug delivery devices, including pre-filled syringes and autoinjectors. These devices are increasingly being used to make medicine administration easier and more convenient for patients, particularly for treatments that can be given outside hospitals and clinics.

Genentech said the facility will be designed to handle both high- and low-volume production. This flexibility will allow the company to adjust manufacturing capacity as demand changes and new medicines are added to its portfolio.

The investment is part of Roche and Genentech’s wider expansion of their US manufacturing network. The companies currently operate 13 manufacturing sites, 15 research and development locations and employ around 25,000 people across 24 locations in eight US states.

The Hillsboro project follows the recent completion of the main structural phase, known as topping out, of Genentech’s new manufacturing facility in Holly Springs, North Carolina.

That facility is being developed to support global manufacturing of Roche’s future metabolic medicine portfolio, including next-generation obesity treatments.

The new Oregon facility is expected to strengthen Genentech’s ability to manufacture medicines using modern delivery devices and support the company’s growing pipeline.

With operations planned for 2031, the Hillsboro investment will also expand Oregon’s role in advanced pharmaceutical manufacturing while creating new long-term employment opportunities in the state.